Central Precocious Puberty Clinical Practice Guidelines And Drug Use Profile In The Brazilian Unified Health System - PP58 - drug use profile and implementation assessment

Sep 29, 2026

Uploaded by Rowan

Central precocious puberty (CPP) is a rare condition marked by early biochemical puberty and physical development before ages eight in girls and nine in boys. Using real-world drug dispensing records from Brazil’s Unified Health System, the study examined implementation of the CPP clinical practice guideline recommending gonadotropin-releasing hormone agonists. Data from 2013 to 2023 were extracted, filtered to ICD-10 code E22.8, and analyzed descriptively with PostgreSQL, showing broad guideline adoption and recent updates to dosing frequency.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Introduction

Methods

Results

Conclusions

PP57 Proposal For Adaptation Of The Pharmaceutical Innovativeness Index Based On Lenacapavir Alex Martins, Ludmila Gargano ([ludgargano@gmail.com](ludgargano@gmail.com)), Francisco Acurcio, Juliana Alvares-Teodoro and Augusto Guerra Jr Introduction: Treatment of HIV-1 infection is based on antiretroviral therapy. A pharmaceutical innovativeness index (PII) was proposed as a tool to evaluate the degree of innovativeness of technologies, initially for cancer treatment. This study aimed to adapt the PII for assessing therapies used in the treatment of people living with multidrug-resistant HIV-1 (MDR-HIV), based on an assessment of lenacapavir. Methods: The PII is structured into four domains: unmet therapeutic need (UTN), added therapeutic value (ATV), study design (SD), and methodological quality (MQ) . The second domain required adaptation to better fit the outcomes typically evaluated in pivotal studies of antiretrovirals for the treatment of MDR-HIV patients. To adapt the PII for antiretroviral therapy innovations, we assessed the innovativeness of lenacapavir as a case study, based on the phase two/three study comparing it to fostemsavir trometamol and its pivotal phase three study. Results: In this adaptation, virological response rate ratio replaced relative risk of mortality in the ATV domain. The proposed scale suggested that a ratio less than one corresponded to “absent” ATV; a ratio between 1.01 and 1.24 to “poor” ATV; between 1.25 and 1.99 to“moderate” ATV; and a ratio of at least two to “maximum” ATV. Lenacapavir was classified as “moderate” for both UTN and ATV domains, as “inadequate” for study design (single-arm trial), and as low risk of bias in the MQ domain. Thus, an innovativeness score of 50 was assigned to lenacapavir. Conclusions: This preliminary case study adaptation provided an important contribution to evaluating the degree of innovativeness of antiretrovirals used in the treatment of people living with MDR-HIV. Maintaining the weights assigned to each domain proposed by the PII, led to an innovation score of 50 for lenacapavir. PP58 Central Precocious Puberty Clinical Practice Guidelines And Drug Use Profile In The Brazilian Unified Health System Rosângela Maria Gomes, Wallace Breno Barbosa, Marta da Cunha Lobo Souto Maior (marta. maior@saude. [gov.br](gov.br)), Ana Carolina de Freitas Lopes, Luciene Fontes Schluckebier Bonan and Amanda Oliveira Lyrio Introduction: Central precocious puberty (CPP) is a rare condition, commonly characterized by early development of biochemical puberty and physical characteristics before the ages of eight (girls) and nine (boys) years. According to the Brazilian clinical practice guideline (CPG) the treatment of CPP includes gonadotropinreleasing hormone agonists. The objective of this study was to verify implementation of the CPP CPG using real-world drug dispensing data from the Brazilian Unified Health System. Methods: Data from drug dispensing in the Brazilian Unified Health System between 2013 and 2023 were extracted by a platform that creates follow-up cohorts for specific diseases (Open Room for Health Intelligence Situation) . Only data for patients with an International Classification of Diseases, 10th Revision category of E22.8 were selected. All records that did not have encrypted user identification or that did not have an approved quantity of medication were excluded. A descriptive analysis was performed using PostgreSQL 24.2 to model the data. Results: A total of147,045individuals with CPP were treated with the recommended drugs in the Unified Health System over the study period. Most patients were female (94%) . The mean age of patients atthe beginning of treatment was 8.8 years (standard deviation 5.3) . The most used drugs were leuprolide (80.2%), triptorelin (17.7%), goserelin (2.0%), and cyproterone acetate (0.2%) . Leuprolide and triptorelin, with a biannual frequency of use, were included in the CPG at the end of 2022 . Conse

FAQs

What condition does this study focus on?

The study focuses on central precocious puberty (CPP), a rare condition involving early onset of biochemical and physical puberty characteristics.

How were the data collected and filtered?

Drug dispensing data from the Brazilian Unified Health System between 2013 and 2023 were extracted, then filtered to include only patients with ICD-10 E22.8 and records with approved medication quantity and encrypted user identification.

Which drugs were most commonly used and what guideline update was reported?

The most used drugs were leuprolide, triptorelin, goserelin, and cyproterone acetate. The document was updated to recommend biannual frequency use of leuprolide and triptorelin to improve adherence.

Sep 29, 2026

Uploaded by Rowan